title: Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
abstract: There has been no literature which reports a case of interstitial lung disease associated with sorafenib. However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib. In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma. Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences.
authors.affiliation: Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan.
authors.forename: Shotaro
authors.initials: S
authors.lastname: Ide
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Soda
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Hakariya
authors.forename: Shinnosuke
authors.initials: S
authors.lastname: Takemoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishimoto
authors.forename: Shinya
authors.initials: S
authors.lastname: Tomari
authors.forename: Toyomitsu
authors.initials: T
authors.lastname: Sawai
authors.forename: Seiji
authors.initials: S
authors.lastname: Nagashima
authors.forename: Masataka
authors.initials: M
authors.lastname: Furukawa
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kohno
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D044466:Asian People; D001557:Benzenesulfonates / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000503:physiopathology; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib